

Ludovic Juen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1160120/publications.pdf>

Version: 2024-02-01

8
papers

121
citations

1478505

6
h-index

1588992

8
g-index

9
all docs

9
docs citations

9
times ranked

188
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. <i>Cancers</i> , 2020, 12, 240.	3.7	49
2	New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6119-6136.	6.4	17
3	A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells. <i>Cancers</i> , 2019, 11, 2043.	3.7	15
4	Innovative Bioconjugation Technology for Antibody-Drug Conjugates: Proof of Concept in a CD30-Positive Lymphoma Mouse Model. <i>Bioconjugate Chemistry</i> , 2021, 32, 595-606.	3.6	13
5	Nonsymmetrical Azocarbonamide Carboxylates as Effective Mitsunobu Reagents. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 7806-7809.	2.4	10
6	Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody-Drug Conjugates. <i>ACS Omega</i> , 2020, 5, 1557-1565.	3.5	10
7	Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential. <i>ChemMedChem</i> , 2021, 16, 1034-1046.	3.2	4
8	Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer. <i>Bioconjugate Chemistry</i> , 2022, 33, 418-426.	3.6	3